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THE purpose of this study was to determine if free or
esterified carnitine could alter fatty acid metabolism and
ameliorate sepsis in lipopolysaccharide (LPS)-treated rats.
Throughout a 96 h observation post-LPS, i.p. administra-
tion of both markedly reduced illness and accelerated
recovery. Carnitine prevented the acute LPS-induced rise
in serum triglycerides (45 + 6, 59 + 5 vs. 83 + 8 mg/ml,
p < 0.001), respectively. This difference was accompanied
by a significant increase in liver lipogenesis in LPS
controls compared to both carnitines and normal rats
(6.1 + 0.3 vs. 3.9 + 0.5, 4.3 + 0.5, and 1.8 + 0.4 Itmol/h,
respectively, p < 0.04). Compared to normal rats, total
liver carnitine was significantly elevated in LPS controls
and even higher in the carnitine groups (357 _+ 40 vs.
736 + 38, 796 + 79, and 1081 + 21nmol/g). The data
suggest that carnitines may be of therapeutic value in
sepsis treatment and one action may be to partition fatty
acids from esterification to oxidation.
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Introduction
Sepsis and endotoxaemia are accompanied by
several disturbances in lipid metabolism. Hyper-
triglyceridaemia is one of these. 1’2 The elevated
serum triglycerides are transported in very low
density lipoprotein (VLDL) and accumulate be-
cause of increased production in the liver
3 and
decreased clearance by peripheral tissues.
Systemic infection is accompanied by increased
hepatic lipogenesis and decreased hepatic mitochon-
drial oxidation of lipids despite a normal or
increased availability of free fatty acids.4 It has been
observed in rats rendered endotoxaemic by
lipopolysaccharide (LPS), that a decreased capacity
for long-chain fatty acyl-CoA oxidation is a
consequence of reduced carnitine palmitoyltransfer-
ase (CPT) activity.
4
Another consequence of sepsis is a decreased
carnitine concentration in muscle and liver.4 It is
well established that free carnitine is necessary for
the transfer of long-chain fatty acids into the
mitochondrial matrix for fl-oxidation by acting as
an acceptor for fatty acyl groups transferred from
acyl CoA by CPT,
6 the rate limiting reaction.
Because of this important function for carnitine
in normal lipid metabolism and since L-carnitine
administration has been shown to increase liver
carnitine7’8 and to counter the symptoms of
carnitine deficiency in humans,9’1 the authors
hypothesized that carnitine and/or novel carnitine
esters may be effective in normalizing lipid
metabolism in sepsis and endotoxaemia.
(C) 1993 Rapid Communications of Oxford ktd
Further, such a metabolic change which increases
energy production and decreases energy storage
may ameliorate the illness. This hypothesis was
tested in LPS-treated rats administered L-carnitine
or the y-hydroxybutyryl ester of isovalerylcarnitine
tartarate (VBT carnitine). The general structure of
this ester is provided in Fig. 1.
Materials and methods
Experimental protocol: Male Sprague Dawley rats
(Hilltop Labs) weighing 250-300 g at the beginning
of the study were held in quarantine for 1 week.
During this time the animals were offered rat chow
and water ad libitum and trained to a 12h
(11 a.m.-11 p.m. dark) reverse light cycle. The
experimental protocol shown in Fig. 2 for animal
use was approved by the Institutional Animal Care
and Use Committee. At -16 h, --8 h, and at zero
time experimental animals were injected i.p. with
L-carnitine (100mg/kg body weight) or VBT
carnitine (to deliver 100mg carnitine/kg) in
NaHCO3, pH 8.0 (0.8 ml). Controls at these same
VBT carnitine
tartarate--COO-
/O
HaN--carnitinemC\
hydroxybutyrate
isovalerate --C--O
FIG. 1. y-Hydroxybutyryl ester of isovalerylcarnitine tartarate (VBT
carnitine).
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FIG. 2. Experimental protocol. At -16 h, -8 h, and at zero time, animals
(17/group) were injected i.p. with NaHCO3 buffer vehicle __. carnitine,
VBTcarnitine or the short-chain acids of VBTcarnitine. At zero time all
animals except the NaHCO3 controls were injected concurrently with
LPS. At 8 h post-LPS the respective groups received a final injection of
NaHCO3 buffer ___
carnitines or short-chain acids. At -29 h animals (six
from each group) were injected i.p. with 3H20, killed at 30 h, and liver,
muscle and blood collected. Tailvein blood was collected at 24 h pre-LPS,
at zero time, and at 3 and 24 h post-LPS. Rats and chow were weighed
at 24 h pre-LPS and at 24 h intervals. Animal health and survival were
monitored regularly for 96 h post-LPS. See methods for specific details.
Car carnitine, Car-X X-VBTcarnitine, LPS lipopolysaccharide.
times received the NaHCO3 vehicle _+ an amount
of tartarate, 2-hydroxybutyrate, and isovalerate
equivalent to that in the VBT-carnitine group. At
zero time all animals except the NaHCO3 controls
were injected concurrently with LPS (24 mg/kg, E.
coli serotype 0127"B8; Sigma) in NaHCO buffer.
This amount of LPS had been predetermined to
produce 30-50% lethality by 48 h. At 8 h post-LPS
the animals received the final i.p. injection of
NaHCO vehicle _+ carnitines as appropriate. At
29 h, fasted rats from each group were selected
randomly for measurement of liver lipogenesis,
liver mitochondrial oxidative capacity, and tissue
carnitine. Each was injected i.p. with H20
(50 mCi, 1Ci/ml, ICN Radiochemicals), a substrate
for fatty acid synthesis and 1 h later weighed and
killed by decapitation. Liver and skeletal muscle
(gastrocnemius) were collected and a small sample
of each was immediately frozen in liquid nitrogen
and stored at -80C until analysed and a blood
sample was obtained. Mitochondria were prepared
from the remaining liver. Tailvein blood from
fasting animals was collected at 24 h pre-LPS, at 0
time just prior to LPS injection, and at 3 h and 24 h
post-LPS. Rats and chow were weighed at 24 h
pre-LPS and at 24 h intervals throughout the
study. Animal survival and health were monitored
hourly for the first 48 h post-LPS and at regular
intervals for an additional 48 h. Health status was
assessed by three independent observers and
animals were ranked as (a) very sick, if totally
inactive, eyes closed, no movement when touched;
(b) sick, if some activity and movement when
touched but no food consumption; (c) fair,
if more active with some food consumption; and
(d) normal, if displaying normal activity with
much improved food consumption.
Analytical procedures:
Triglycerides. A commercial kit (GPO-Trinder,
Sigma) was used to measure triglyceride levels
colorimetrically from blood collected from fasted
animals and treated with EDTA. In accordance
with the manufacturer’s directions, a plasma blank
was carried through the procedure with each
sample, to correct for haemolysis.
Lipogenesis in vivo. Liver samples (1 g) collected 1 h
after the i.p. injection of H20 (50 mCi) and 30 h
post-LPS were processed precisely as described by
Feingold and Grunfeld.
3 Briefly, liver was homo-
genized and liver lipids were saponified overnight
by refluxing in alcoholic KOH. 14[C]-Oleic acid
(20 000 dpm, ICN Radiochemicals) was added as an
internal standard to monitor the efficiency of [H]
fatty acid recovery. The nonsaponifiable lipids were
extracted by several treatments with petroleum
ether (100ml total). The fatty acid salts in the
saponifiable fraction were acidified with con-
centrated HC1 (pH < 2) and the fatty acids extracted
into petroleum ether (75 ml) which was evaporated
under nitrogen. Fatty acids were resuspended in
chloroform (5.0 ml) and an aliquot was added to
Scintiverse (Fisher Scientific), a biodegradable
liquid scintillant, and radioactivity monitored by
liquid scintillation counting. Counts were auto-
matically corrected for [H] (<0.1%) and [14C]
< 12.0%) spillover. Calculations were corrected for
background counts and recovery (85%) of the
internal standard. The specific activity of the H20
predetermined to be completely equilibriated prior
to 1 h, was determined by counting the dpm in 1 ml
of plasma from each animal and dividing by mmol
of H20 (52 mmol/ml) per ml of plasma.
Tissue carnitine. Free and total carnitine in liver
and muscle were determined by the radioisotopic
assay described by McGarry and Foster.
11 An
aliquot of a protein-free supernatant prepared by
perchloric acid treatment of the tissue homogenate
was neutralized and assayed for free carnitine.
Another aliquot was treated with alkali to hydrolyse
short-chain carnitine esters then neutralized and
assayed for total acid-soluble carnitine. In both
cases, the carnitine containing supernatant was
incubated with [14C] acetyl CoA (53 mCi/mmole,
ICN Radiochemicals) in the presence of carnitine
acetyltransferase (Sigma) to yield acetylcarnitine
and coenzyme A which was trapped by N-
ethylmaleimide (Sigma). Unreacted [14C] acetyl CoA
was removed with the ion exchange resin, Dowex
2 (Sigma) and radioactivity remaining in the
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supernatant representing tissue carnitine, was
determined by liquid scintillation counting. Dupli-
cate portions of each tissue were carried through
the procedure and carnitine was assayed in triplicate
on each supernatant. Radioactive counts were
corrected for background and authentic I-carnitine
(Sigma Tau SpA, Italy) served as the standard.
Mitochondrial respiration. Mitochondria were pre-
pared from the livers of fasted rats 30 h post-LPS
following the procedure of Murphy et alo
12
Mitochondrial protein was determined by the
method of Lowry et al.
13 with bovine serum
albumin as standard. The mitochondrial yield was
128 q-15mg protein/liver and did not vary
significantly among animal groups. State 3
(ADP-stimulated) respiration was measured polaro-
graphically with a Clark oxygen electrode (Yellow
Springs Instrument Co.) at 37C essentially
according to the methods of Murphy et al.12 Malate
(5 mM) and ADP (0.5 mM) were present in all
measurements. Glutamate, palmitoylcarnitine, pal-
mitoyl CoA and carnitine were present at
concentrations of 5 mM, 0.04 mM, 0.04 mM, and
2 mM, respectively. All chemicals in the assay were
products of Sigma.
Statistical analyses" Data are expressed as the mean
-+- S.E.M. Statistical analyses were performed using
Student’s t-test and ANOVA followed by post-
ANOVA (Tukey).
Results
Animal health and survival: There was a striking
difference in the health of the LPS-treated rats in
the presence and absence of carnitine and
VBTcarnitine (Table 1). Within 2h of LPS
treatment, five of 17 animals in the LPS group were
very sick and eight were sick. In the LPS + carnitine
groups all 17 (VBTCar) and 14 (Car) of the animals
were in fair to normal health. At 4 h, when all LPS
animals were very sick (17), only seven to eight
animals in the carnitine groups were very sick. By
30 h the nine survivors from the LPS group ranged
from very sick (one), to sick (five), to fair (two), to
normal (one). The surviving carnitine animals
(nine) and the VBTcarnitine animals (twelve) were
restored to fair or normal health. Over the 96 h
.observation period there were eight deaths in the
LPS group, seven deaths in carnitine group and five
deaths in the VBTcarnitine group.
Food consumption and body weight" Food consumption
(Table 2) in the 0-24 h after LPS treatment dropped
to < 1.0 g/rat with only one rat eating in the LPS
group while seven to eight of the animals in both
carnitine groups continued to eat. In the 24-48 h
after LPS treatment the LPS animals had an average
food intake of 8.4 g or 25% of the normal food
consumption (34.4-+-1.1 g) while the carnitine
groups consumed an average of nearly twice that
amount.
Table 1. The variation of survival and health with time after LPS
Treatment Time after LPS
2h 4h 24 h 30 h 96 h
Dead VS S F N Dead VS
LPS 0 5 8 4 0 0 16
LPS+Car 0 0 0 7 10 0 7
LPS + VBTCar 0 0 3 6 8 0 8
S F N
0 0
10 0 0
8 0
Dead VS S F N Dead VS S F N Dead
7 3 6 0 7 2 6 2 0 8
3 6 5 3 0 6 0 7 2 7
5 0 8 4 0 5 0 0 10 2 5
n 17 rats/group. Scale" VS very sick" S sick" F fair" N normal. After LPS treatment, animals were monitored hourly for
96 h.
Table 2. The variation of food consumption with time
Treatment Food consumption (g) S Food consumption (g) S
Day 1, pre-LPS Day 1, post-LPS Day 2, post-LPS
LPS 27.1 _+ 1.6 0.4 _+ 0.3 1/10 8.4 _+ 2.6 4/4
LPS + Car 28.9 _+ 0.9 1.6 _+ 0.9 7/14 14.8 -t- 2.1 4/4
LPS +VBTCar 30.3 _+ 1.4 1.5 ___
0.5 8/12 14.9 _+ 3.3 6/6
Values Mean _+ S.E.M. n 17.
Controls (eight) consumed an average of 27.1 ___
1.1, 35.4 -t- 1.1, and 34.4 ___
1.1 g of diet at these respective
times.
S number of survivors consuming food.
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Table 3. The variation of body weight with time
Treatment Initial
body weight (g)
Day 1, post-LPS Day 2, post-LPS
LPS 277 _+ 5 257 -I- 6 256 -I- 10
LPS + Car 279 -I- 2 262 -t- 3 261 -I- 7
LPS +VBTCar 277 -t- 2 271 _+ 4 271 -t- 5
Values mean _+ S.E.M. n 17.
Controls (eight) weighed an average of 276 _+ 4, 290 _+ 4,
287 _+ g at these respective times.
Body weights (Table 3) were not significantly
different among the LPS, carnitine, and VBTcarni-
tine groups, although the carnitine and VBTcarni-
tine groups averaged 5 and 15 g heavier at 24 h
(279-b2 and 262-b3g) and 48h (261___7 and
271 __+ 5 g) after LPS, respectively. Normal controls
at these same times weighed 290_+ 4g and
2874- lg.
Serum trigJycerides" Serum triglyceride levels (Table 4)
measured at 3 h after LPS treatment had increased
an average of 50 mg/dl in the LPS group but only
16 mg/dl in the carnitine group and 27 mg/dl in the
VBTcarnitine group. The difference between the
LPS and both carnitine groups was statistically
significant. By 30 h after LPS treatment serum
triglycerides were still elevated by 20 mg/dl in the
LPS group but were restored to normal in the
carnitine groups.
Liver lipogenesis in vivo" Fatty acid biosynthesis de novo
(Table 5) was significantly higher (> three-fold) in
the LPS group than in normal untreated controls.
When either carnitine or VBTcarnitine was given
to the LPS treated animals, fatty acid biosynthesis
significantly decreased to a level which was only
1.4-1.6 fold that in normal controls.
Tissue carnitine" The total and free liver carnitine
levels (Table 6) in the LPS-treated rats in the
presence or absence of the administered carnitines
Table 4. The variation of serum triglyceride levels with time
Serum triglyceride level (mg/dl)
Treatment Pre-LPS Post-LPS (h)
3 30
LPS 33 + 3 83 _. 8a’b 53 + 19
LPS + Car 29 -I- 3 45 _
6 32 _+ 4
LPS + VBTCar 32 -t_- 2 59 -
5 27 3
Values mean -t- S.E.M. n 17.
aSignificantly higher than pre-LPS (p 0).
bSignificantly higher than LPS + Car and LPS +VBTCar
(p < 0.001 ).
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Table 5. The variation of liver lipogenesis in vivo
Lipogenesis
Treatment /mol/g/h /mol/liver/h
LPS 6.1 -I- 0.3 67.8 -I- 4.6
LPS + Car 3.9 _+ 0.4 44.7 _+ 6.3
LPS + VBTCar 4.3 + 0.5 47.6 + 7.5
None 1.8 + 0.4b 24.9 + 5.5b
29 h post-LPS, rats were injected i.p. with 3H20 (50 mCi) and
h later the liver was removed into liquid nitrogen. Liver lipids
were saponified, extracted, and isotope incorporation into fatty
acids was measured by liquid scintillation counting.
Values mean -t- S.E.M. for n 6.
aSignificantly greater than the other experimental groups and
untreated control (p _< 0.04).
bSignificantly less than the experimental groups (p < 0.01 ).
Table 6. Liver carnitine levels at 30 h post-LPS
Carnitine (nmol/g)
Treatment Free Total
LPS 302 _+ 31 736 _+ 38
LPS + Car 370 -t- 28 796 ___
79
LPS + VBTCar 429 ___
29b 1081 ___
21 b
None 198 _+ 27 357 _+ 40
Values mean __+ S.E.M. n 6.
Liver was quickly excised into liquid nitrogen from normal
controls injected i.p. with vehicle or from experimental animals
30 h after injection with LPS -t- carnitines in bicarbonate buffer
as described under Methods. Free and total carnitine were
determined by radioactivity assay.
aSignificantly less than all other groups (p < 0.04).
bSignificantly greater than all other groups (p _< 0.03).
were significantly higher (two- to three-fold) than
untreated controls. The total and free carnitine
levels were also higher in the LPS animals treated
with carnitine (8% and 23%, respectively) or
VBTcarnitine (47% and 42%, respectively) than in
the LPS groups. The latter difference was
statistically significant. In the LPS plus carnitine
animals, free carnitine accounts completely for the
increase in total carnitine while in the LPS plus
VBTcarnitine animals, the increase in total carnitine
is due to increases in both free and esterified
carnitine (accounts for 66% of the increase).
The total and free muscle carnitine levels (Table
7) in the LPS group were slightly lower, though
not significantly, than in the LPS animals treated
with carnitine or VBTcarnitine and lower than in
normal muscle. Total and free muscle carnitine in
the LPS animals treated with carnitine or VBT
carnitine were the same as in normal untreated
muscle.
Mitochondrial respiration: Mitochondrial state 3 re-
spiration was not significantly different among the
LPS -t- carnitine or VBTcarnitine treatment groupsAmelioration of sepsis by carnitines
Table 7. Skeletal muscle carnitine levels at 30 h post-LPS
Carnitine (nmol/g)
Treatment Free Total
LPS 679 _+ 43 829 _+ 56
LPS + Car 729 _+ 59 921 ___
77
LPS + VBTCar 807 _+ 51 963 _+ 66
None 783 __
81 917 _+ 81
Values mean + S.E.M. n 6.
Skeletal muscle was quickly excised into liquid nitrogen from
normal controls injected i.p. with vehicle or from experimental
animals 30 h after injection with LPS _+ carnitines in bicarbonate
buffer as described under Methods. Free and total carnitine were
determined by assay of radioactivity.
or controls with either glutamate, palmitoylcarni-
tine or palmitoyl CoA plus carnitine as substrates.
Oxygen consumption measured as ng atoms
O2/min/mg protein with glutamate in the LPS
group was 202.8 8.1 compared to 202.7 _+ 15.4,
192.8 8.7, and 179.5 -+- 3.0 in the LPS-carnitine,
LPS, VBTcarnitine, and controls animals, respec-
tively, with palmitoylcarnitine 138.7 __+ 7.1 com
pared to 159.6 _--+- 9.3, 131.5 8.7, and 129.3 _-q-
6.8, and with palmitoyl CoA plus carnitine
70.8 __+ 4.3 compared to 62.9 7.1, 67.4 _+ 5.5 and
63.5 1.6, for n-- 5 animals per group.
Discussion
Sepsis and endotoxaemia lead to disturbances in
lipid metabolism. Notably, hepatic energy produc-
tion from fatty acid oxidation is suppressed under
circumstances where there is an overall body
increase in oxygen consumption and an increased
tissue demand for oxidative substrates. In this
study, the potential of carnitine and a novel
carnitine derivative, the 2-hydroxybutyryl ester of
isovalerylcarnitine tartarate (VBTcarnitine) to nor-
malize hepatic lipid metabolism was studied in
LPS-treated rats.
LPS treatment produced the expected rapid onset
of illness described by others (for example
see Reference 4). Carnitine and VBTcarnitine
markedly delayed and decreased the severity of
illness (Table 1). There were no detectable
differences in effectiveness between the two. The
ester form of carnitine has been demonstrated to be
more effective in the treatment of some disorders
such as heart muscle14 and brain ischaemia.
15
Carnitine and VBTcarnitine may have decreased the
lethality of LPS as there were seven and five deaths
in these groups, respectively and eight deaths in the
LPS group. Takeyama et al.4 have reported that
carnitine (500 mg/kg body weight given i.p. at 16 h
and 30 min pre-LPS) increases the survival rate in
LPS-treated rats. Consistent with less illness in the
LPS groups treated with carnitine or VBTcarnitine
were greater food consumption and less loss of
body weight.
Serum triglycerides were significantly lower in
both carnitine treatment groups relative to the
untreated LPS animals (Table 4) and these results
are in agreement with those of Takeyama et al.4 who
observed lower serum triglycerides post-LPS in
carnitine-treated animals. Decreased hepatic synth-
esis of fatty acids de novo accounts in part, if not
fully, for the lower serum triglycerides in the LPS
animals treated with carnitine or VBTcarnitine
(Table 5). With less fatty acid moving toward
esterification, less triglyceride is packaged and
secreted in liver VLDL.
Since hepatic fatty acid synthesis and fatty acid
oxidation are reciprocal events,
6 the authors
suspect that hepatic fatty acid oxidation is
stimulated in the LPS groups treated with carnitine
or VBTcarnitine. This would be consistent with the
observations that hepatic CPT activity declines4 and
malonyl CoA levels increase4’7 in septic animals.
Further, hepatic carnitine levels are reported to
increase with carnitine administration in septic
animals,
4 carnitine is essential for CPT catalysed
translocation of fatty acids into the mitochondria
for oxidation,
6 and the decrease in hepatic
lipogenesis discussed above would be expected to
lower malonyl CoA, a potent CPT inhibitor. In the
present study the maximum capacity of isolated
liver mitochondria for ATP synthesis (state 3
respiration) with lipid and non-lipid substrates was
not different in the LPS groups with or without
carnitine treatment. This finding is in agreement
with that of Takeyama et al. and indicates that any
possible change in CPT activity that may occur
during septicaemia is insufficient to limit the
maximum rate of oxidative energy metabolism
measured in vitro.
Measurement of liver carnitine levels (Table 6)
revealed a significant increase not only in the LPS
animals treated with carnitine or VBT carnitine but
also in the rats treated only with LPS. This finding
was unexpected since liver carnitine levels are
reported to decrease in sepsis.
4 However, the
observed increase may be controlled by glucagon
which increases in sepsis.
9 Injection of glucagon is
reported to increase liver carnitine in rats2 and
glucagon also stimulates carnitine uptake in isolated
hepatocytes.
2 Elevated liver carnitine in the LPS
treated rats as well as in the LPS animals treated
with the carnitines diminishes the argument that a
differential in liver carnitine levels between the two
groups is a determinant of fatty acid metabolism,
that is, oxidation vs. esterification. Clearly, addi-
tional studies will be necessary to determine the
mechanism of action of carnitine and carnitine
derivatives in ameliorating sepsis.
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